MX387753B - Proteínas de unión a calicreína en plasma y usos de las mismas para tratar el angioedema hereditario. - Google Patents
Proteínas de unión a calicreína en plasma y usos de las mismas para tratar el angioedema hereditario.Info
- Publication number
- MX387753B MX387753B MX2016009428A MX2016009428A MX387753B MX 387753 B MX387753 B MX 387753B MX 2016009428 A MX2016009428 A MX 2016009428A MX 2016009428 A MX2016009428 A MX 2016009428A MX 387753 B MX387753 B MX 387753B
- Authority
- MX
- Mexico
- Prior art keywords
- plasma kallikrein
- binding proteins
- hereditary angioedema
- treat hereditary
- treat
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/03—Phosphotransferases with a nitrogenous group as acceptor (2.7.3)
- C12Y207/03002—Creatine kinase (2.7.3.2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21034—Plasma kallikrein (3.4.21.34)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461929716P | 2014-01-21 | 2014-01-21 | |
| US201461944361P | 2014-02-25 | 2014-02-25 | |
| US201462021397P | 2014-07-07 | 2014-07-07 | |
| PCT/US2015/012212 WO2015112578A1 (en) | 2014-01-21 | 2015-01-21 | Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016009428A MX2016009428A (es) | 2017-04-13 |
| MX387753B true MX387753B (es) | 2025-03-18 |
Family
ID=53681890
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016009428A MX387753B (es) | 2014-01-21 | 2015-01-21 | Proteínas de unión a calicreína en plasma y usos de las mismas para tratar el angioedema hereditario. |
| MX2021013665A MX2021013665A (es) | 2014-01-21 | 2016-07-20 | Proteinas de union a calicreina en plasma y usos de las mismas para tratar el angioedema hereditario. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021013665A MX2021013665A (es) | 2014-01-21 | 2016-07-20 | Proteinas de union a calicreina en plasma y usos de las mismas para tratar el angioedema hereditario. |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US11084884B2 (enExample) |
| EP (3) | EP4722720A3 (enExample) |
| JP (4) | JP6845012B2 (enExample) |
| KR (4) | KR20220107077A (enExample) |
| CN (2) | CN116585468A (enExample) |
| AU (3) | AU2015209481C1 (enExample) |
| BR (1) | BR112016016916B1 (enExample) |
| CA (1) | CA2937329C (enExample) |
| DK (1) | DK3096798T3 (enExample) |
| EA (1) | EA038532B1 (enExample) |
| ES (2) | ES3065185T3 (enExample) |
| IL (3) | IL246864B (enExample) |
| MX (2) | MX387753B (enExample) |
| NZ (2) | NZ761006A (enExample) |
| PL (2) | PL3096798T3 (enExample) |
| PT (1) | PT3096798T (enExample) |
| WO (1) | WO2015112578A1 (enExample) |
| ZA (2) | ZA201605342B (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2905545T3 (es) | 2010-01-06 | 2022-04-11 | Takeda Pharmaceuticals Co | Proteínas de unión a calicreína plasmática |
| KR102011156B1 (ko) | 2011-01-06 | 2019-08-16 | 다이액스 코포레이션 | 혈장 칼리크레인 결합 단백질 |
| EP4234583A3 (en) | 2013-01-20 | 2024-01-24 | Takeda Pharmaceutical Company Limited | Evaluation and treatment of bradykinin-mediated disorders |
| JP2016513682A (ja) | 2013-03-15 | 2016-05-16 | ダイアックス コーポレーション | 抗血漿カリクレイン抗体 |
| CN105873951A (zh) | 2013-10-21 | 2016-08-17 | 戴埃克斯有限公司 | 用于确定血浆激肽释放酶系统生物标记的试验 |
| CN110658337B (zh) | 2013-10-21 | 2023-06-16 | 武田药品工业株式会社 | 自身免疫性疾病的诊断和治疗 |
| ES3065185T3 (en) | 2014-01-21 | 2026-05-04 | Takeda Pharmaceuticals Co | Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema |
| IL247942B (en) | 2014-03-27 | 2022-09-01 | Dyax Corp | Compositions and methods for drops in macular edema as a result of diabetes |
| CA3290174A1 (en) * | 2015-03-30 | 2026-03-02 | Takeda Pharmaceutical Company Limited | Plasma kallikrein inhibitors and uses thereof for preventing hereditary angioedema attack |
| WO2017035263A1 (en) * | 2015-08-24 | 2017-03-02 | Biocryst Pharmaceuticals, Inc. | Compositions comprising a plasma kallikrein inhibitor |
| EA201891002A1 (ru) * | 2015-10-19 | 2018-11-30 | Дайэкс Корп. | Иммунологический анализ для определения расщепленного высокомолекулярного кининогена |
| US11286307B2 (en) * | 2015-12-11 | 2022-03-29 | Takeda Pharmaceutical Company Limited | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack |
| WO2018053244A1 (en) * | 2016-09-16 | 2018-03-22 | Dyax Corp. | Protein biomarkers for diseases associated with the contact activation system |
| KR102569559B1 (ko) | 2016-09-16 | 2023-08-23 | 다케다 파머수티컬 컴패니 리미티드 | 유전성 혈관부종에 대한 rna 바이오마커 |
| KR20200067195A (ko) * | 2017-10-18 | 2020-06-11 | 리젠엑스바이오 인크. | 완전-인간 번역후 변형된 항체 치료제 |
| CN110944675B9 (zh) | 2017-12-01 | 2024-08-09 | 苏州瑞博生物技术股份有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| HRP20250277T1 (hr) | 2017-12-01 | 2025-05-09 | Suzhou Ribo Life Science Co., Ltd. | Dvolančani oligonukleotid, sastav i konjugat koji sadrži dvolančani oligonukleotid, postupak njihove pripreme i upotreba |
| WO2019105414A1 (zh) | 2017-12-01 | 2019-06-06 | 苏州瑞博生物技术有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| CN118291456A (zh) | 2017-12-01 | 2024-07-05 | 苏州瑞博生物技术股份有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| JP7360716B2 (ja) | 2017-12-01 | 2023-10-13 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | 核酸、当該核酸を含む組成物および複合体ならびに調製方法と使用 |
| CN110959011B (zh) | 2017-12-29 | 2023-03-28 | 苏州瑞博生物技术股份有限公司 | 缀合物及其制备方法和用途 |
| WO2020038377A1 (zh) | 2018-08-21 | 2020-02-27 | 苏州瑞博生物技术有限公司 | 一种核酸、含有该核酸的药物组合物和缀合物及其用途 |
| JP7376952B2 (ja) | 2018-09-30 | 2023-11-09 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | ｓｉＲＮＡ複合体及びその調製方法と使用 |
| JP7507495B2 (ja) | 2018-12-28 | 2024-06-28 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | 核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用 |
| US12163956B2 (en) | 2019-02-21 | 2024-12-10 | Takeda Pharmaceutical Company Limited | Lateral flow immunoassay for measuring functional C1-esterase inhibitor (C1-INH) in plasma samples |
| KR20210142006A (ko) * | 2019-03-14 | 2021-11-23 | 다케다 파머수티컬 컴패니 리미티드 | 유전성 혈관부종 발작의 치료를 위한 혈장 칼리크레인 저해제 및 이의 용도 |
| JP7610848B2 (ja) | 2019-05-22 | 2025-01-09 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | 核酸、薬物組成物及び複合体ならびに調製方法と使用 |
| CN113286888B (zh) | 2019-05-22 | 2023-12-22 | 苏州瑞博生物技术股份有限公司 | 核酸、药物组合物与缀合物及制备方法和用途 |
| CN113227376B (zh) | 2019-05-22 | 2024-04-09 | 苏州瑞博生物技术股份有限公司 | 核酸、药物组合物与缀合物及制备方法和用途 |
| CN113891939B (zh) * | 2019-05-24 | 2024-04-02 | 苏州瑞博生物技术股份有限公司 | 核酸、药物组合物与缀合物及制备方法和用途 |
| CN113795582B (zh) | 2019-05-24 | 2024-05-24 | 苏州瑞博生物技术股份有限公司 | 核酸、药物组合物与缀合物及制备方法和用途 |
| AU2020392243A1 (en) | 2019-11-28 | 2022-06-16 | Regenxbio Inc. | Microdystrophin gene therapy constructs and uses thereof |
| AU2021209045A1 (en) | 2020-01-13 | 2022-07-28 | Takeda Pharmaceutical Company Limited | Plasma kallikrein inhibitors and uses thereof for treating pediatric hereditary angioedema attack |
| WO2021202948A2 (en) * | 2020-04-04 | 2021-10-07 | Dyax Corp. | Plasma kallikrein inhibitors and uses thereof for treating acute respiratory distress syndrome |
| EP4634234A1 (en) * | 2022-12-13 | 2025-10-22 | Astria Therapeutics, Inc. | Anti-plasma kallikrein antibody dosing regimens for treating plasma kallikrein associated disorders |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
| MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
| US5444156A (en) * | 1985-07-12 | 1995-08-22 | Temple University-Of The Commonwealth System Of Higher Education | Monoclonal antibodies to human plasma prekallikrein |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| EP0296171A4 (en) | 1986-03-03 | 1989-11-07 | Brigham & Womens Hospital | METHOD FOR EVALUATING NEPHROTOXICITY. |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US4881175A (en) | 1986-09-02 | 1989-11-14 | Genex Corporation | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| US4704692A (en) | 1986-09-02 | 1987-11-03 | Ladner Robert C | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| US5045452A (en) | 1988-09-02 | 1991-09-03 | Brigham And Women's Hospital | Method for evaluating nephrotoxicity |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| CA2180950C (en) | 1994-01-11 | 2005-03-29 | William Markland | Kallikrein-inhibiting "kunitz domain" proteins and analogues thereof |
| US6057287A (en) | 1994-01-11 | 2000-05-02 | Dyax Corp. | Kallikrein-binding "Kunitz domain" proteins and analogues thereof |
| US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
| DE19632772A1 (de) | 1996-08-14 | 1998-02-19 | Basf Ag | Neue Benzamidine |
| US5840871A (en) | 1997-01-29 | 1998-11-24 | Incyte Pharmaceuticals, Inc. | Prostate-associated kallikrein |
| US6913900B2 (en) | 2001-08-29 | 2005-07-05 | Nippon Zoki Pharmaceutical Co., Ltd. | Plasma prekallikrein activation and kallikrein production assay |
| US20030138417A1 (en) | 2001-11-08 | 2003-07-24 | Kaisheva Elizabet A. | Stable liquid pharmaceutical formulation of IgG antibodies |
| PT2298278E (pt) | 2002-06-07 | 2016-02-25 | Dyax Corp | Prevenção e redução da perda de sangue e resposta inflamatória |
| US7132100B2 (en) | 2002-06-14 | 2006-11-07 | Medimmune, Inc. | Stabilized liquid anti-RSV antibody formulations |
| JP4653660B2 (ja) | 2003-09-04 | 2011-03-16 | 独立行政法人理化学研究所 | ＴＧＦ−β活性化制御領域の切断面を認識する抗体 |
| EP1713929A2 (en) | 2004-02-03 | 2006-10-25 | Bayer HealthCare AG | Diagnostics and therapeutics for diseases associated with plasma kallikrein (klkb1) |
| CA2575791A1 (en) | 2004-08-03 | 2006-02-16 | Dyax Corp. | Hk1-binding proteins |
| US7235530B2 (en) | 2004-09-27 | 2007-06-26 | Dyax Corporation | Kallikrein inhibitors and anti-thrombolytic agents and uses thereof |
| DK1854477T3 (en) | 2006-03-16 | 2016-11-28 | Dyax Corp | Peptide inhibitors of plasma kallikrein for use in the treatment of eye disorders |
| CN101495468A (zh) * | 2006-07-31 | 2009-07-29 | 艾克提弗赛特制药股份有限公司 | 血浆激肽释放酶抑制剂 |
| EP2051707B1 (en) | 2006-07-31 | 2013-07-17 | Activesite Pharmaceuticals, Inc. | Inhibitors of plasma kallikrein |
| KR100846354B1 (ko) | 2007-03-21 | 2008-07-15 | (주) 프로탄바이오 | 혈청 당단백질부터 분리한 폐암 진단용 마커 |
| EP2182978A4 (en) * | 2007-07-20 | 2012-03-21 | Sanomune Inc | TISSUE KALLIKREIN FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID PROTEIN |
| WO2009026539A1 (en) | 2007-08-23 | 2009-02-26 | Genzyme Corporation | Treatment with kallikrein inhibitors |
| MX2011000071A (es) | 2008-07-02 | 2011-05-03 | Emergent Product Dev Seattle | Inmunoterapeuticos de interleucina-6 (il6). |
| JP2013516389A (ja) | 2009-01-06 | 2013-05-13 | ダイアックス コーポレーション | カリクレイン阻害剤による粘膜炎治療 |
| CN101928346B (zh) | 2009-07-31 | 2013-01-16 | 华中科技大学同济医学院附属同济医院 | 一种抗人组织激肽释放酶单克隆抗体及其制备 |
| ES2905545T3 (es) | 2010-01-06 | 2022-04-11 | Takeda Pharmaceuticals Co | Proteínas de unión a calicreína plasmática |
| KR102011156B1 (ko) | 2011-01-06 | 2019-08-16 | 다이액스 코포레이션 | 혈장 칼리크레인 결합 단백질 |
| EP2697196A1 (en) | 2011-04-13 | 2014-02-19 | Activesite Pharmaceuticals, Inc. | Prodrugs of inhibitors of plasma kallikrein |
| UY34054A (es) | 2011-05-02 | 2012-11-30 | Millennium Pharm Inc | FORMULACIÓN PARA ANTICUERPO ANTI-a(alfa)4B(Beta)7 |
| WO2013123114A2 (en) | 2012-02-16 | 2013-08-22 | Santarus, Inc. | Antibody formulations |
| US9216219B2 (en) | 2012-06-12 | 2015-12-22 | Novartis Ag | Anti-BAFFR antibody formulation |
| EP4234583A3 (en) | 2013-01-20 | 2024-01-24 | Takeda Pharmaceutical Company Limited | Evaluation and treatment of bradykinin-mediated disorders |
| DK2946206T3 (en) | 2013-01-20 | 2019-04-15 | Dyax Corp | EVALUATION, ANALYSIS AND TREATMENT OF PKAL-MEDIATED DISORDERS |
| JP2016513682A (ja) | 2013-03-15 | 2016-05-16 | ダイアックス コーポレーション | 抗血漿カリクレイン抗体 |
| KR20140119396A (ko) | 2013-03-29 | 2014-10-10 | 삼성전자주식회사 | 단백질 약물의 액상 제형 |
| CN105873951A (zh) | 2013-10-21 | 2016-08-17 | 戴埃克斯有限公司 | 用于确定血浆激肽释放酶系统生物标记的试验 |
| ES3065185T3 (en) | 2014-01-21 | 2026-05-04 | Takeda Pharmaceuticals Co | Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema |
| IL247942B (en) | 2014-03-27 | 2022-09-01 | Dyax Corp | Compositions and methods for drops in macular edema as a result of diabetes |
| CA3290174A1 (en) | 2015-03-30 | 2026-03-02 | Takeda Pharmaceutical Company Limited | Plasma kallikrein inhibitors and uses thereof for preventing hereditary angioedema attack |
| US11286307B2 (en) | 2015-12-11 | 2022-03-29 | Takeda Pharmaceutical Company Limited | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack |
| IL314752A (en) * | 2016-09-16 | 2024-10-01 | Takeda Pharmaceuticals Co | Metabolite biomarkers for diseases associated with the contact activation system |
| EP3678551B1 (en) | 2017-09-05 | 2023-06-28 | Sanolla Ltd | Electronic stethoscope with enhanced features |
| EP3843840A1 (en) | 2018-08-30 | 2021-07-07 | Dyax Corp. | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack |
| KR20210142006A (ko) | 2019-03-14 | 2021-11-23 | 다케다 파머수티컬 컴패니 리미티드 | 유전성 혈관부종 발작의 치료를 위한 혈장 칼리크레인 저해제 및 이의 용도 |
| AU2021209045A1 (en) | 2020-01-13 | 2022-07-28 | Takeda Pharmaceutical Company Limited | Plasma kallikrein inhibitors and uses thereof for treating pediatric hereditary angioedema attack |
-
2015
- 2015-01-21 ES ES20209536T patent/ES3065185T3/es active Active
- 2015-01-21 EA EA201691470A patent/EA038532B1/ru unknown
- 2015-01-21 MX MX2016009428A patent/MX387753B/es unknown
- 2015-01-21 EP EP25221825.0A patent/EP4722720A3/en active Pending
- 2015-01-21 US US15/113,297 patent/US11084884B2/en active Active
- 2015-01-21 KR KR1020227025028A patent/KR20220107077A/ko not_active Ceased
- 2015-01-21 NZ NZ761006A patent/NZ761006A/en unknown
- 2015-01-21 ES ES15740774T patent/ES2856076T3/es active Active
- 2015-01-21 JP JP2016547570A patent/JP6845012B2/ja active Active
- 2015-01-21 PL PL15740774T patent/PL3096798T3/pl unknown
- 2015-01-21 CA CA2937329A patent/CA2937329C/en active Active
- 2015-01-21 KR KR1020167022785A patent/KR102424183B1/ko active Active
- 2015-01-21 PL PL20209536.0T patent/PL3848057T3/pl unknown
- 2015-01-21 DK DK15740774.3T patent/DK3096798T3/da active
- 2015-01-21 NZ NZ723369A patent/NZ723369A/en unknown
- 2015-01-21 CN CN202310760869.5A patent/CN116585468A/zh active Pending
- 2015-01-21 EP EP15740774.3A patent/EP3096798B1/en active Active
- 2015-01-21 CN CN201580010172.XA patent/CN106132442B/zh active Active
- 2015-01-21 EP EP20209536.0A patent/EP3848057B1/en active Active
- 2015-01-21 KR KR1020247010766A patent/KR20240049627A/ko active Pending
- 2015-01-21 WO PCT/US2015/012212 patent/WO2015112578A1/en not_active Ceased
- 2015-01-21 PT PT157407743T patent/PT3096798T/pt unknown
- 2015-01-21 KR KR1020247006911A patent/KR102903403B1/ko active Active
- 2015-01-21 BR BR112016016916-6A patent/BR112016016916B1/pt active IP Right Grant
- 2015-01-21 AU AU2015209481A patent/AU2015209481C1/en active Active
-
2016
- 2016-07-20 MX MX2021013665A patent/MX2021013665A/es unknown
- 2016-07-20 IL IL246864A patent/IL246864B/en active IP Right Grant
- 2016-08-02 ZA ZA201605342A patent/ZA201605342B/en unknown
-
2018
- 2018-12-12 IL IL263669A patent/IL263669B/en active IP Right Grant
-
2019
- 2019-09-12 JP JP2019166361A patent/JP7164502B2/ja active Active
-
2020
- 2020-07-28 ZA ZA2020/04653A patent/ZA202004653B/en unknown
- 2020-09-02 US US17/010,354 patent/US12384854B2/en active Active
- 2020-09-28 AU AU2020244370A patent/AU2020244370B2/en active Active
- 2020-10-14 IL IL278062A patent/IL278062B/en unknown
-
2022
- 2022-10-20 JP JP2022168140A patent/JP2023015087A/ja active Pending
-
2024
- 2024-05-23 AU AU2024203436A patent/AU2024203436A1/en active Pending
- 2024-09-03 JP JP2024151126A patent/JP2024170495A/ja active Pending
-
2025
- 2025-07-08 US US19/262,325 patent/US20260035482A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021013665A (es) | Proteinas de union a calicreina en plasma y usos de las mismas para tratar el angioedema hereditario. | |
| AU2016249002B2 (en) | Compositions for modulating C90RF72 expression | |
| CL2018001152A1 (es) | Composiciones y métodos para el tratamiento del cáncer | |
| ZA201803661B (en) | Compositions and methods for decreasing tau expression | |
| IL255615A (en) | Use of cannabis to treat fibromyalgia, methods and compositions thereof | |
| BR112017018954A2 (pt) | uso de forma mutante de proteína ras e método para tratar câncer | |
| CO2017007121A2 (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades | |
| IL251759B (en) | Compositions and methods for treating insomnia | |
| IL252418B (en) | Envenomation therapies and related pharmaceutical compositions, systems and kits | |
| BR112017005598A2 (pt) | macrociclos peptidomiméticos e usos dos mesmos | |
| CO6950477A2 (es) | Agentes inductores de la apoptosis que pueden usarse para tratar el cáncer y las enfermedades inmunes y autoinmunes | |
| DK2914630T3 (da) | Hidtil ukendte antigen-bindende proteiner og deres anvendelse som adresseringsprodukt til behandling af kræft | |
| IL272246A (en) | Compositions and methods for treating galactosemia | |
| MX2015003701A (es) | Composiciones para tratamiento. | |
| IL257764B (en) | Methods for treatment of diseases | |
| IL262929A (en) | Composition, and application and pharmaceutical preparation thereof | |
| MX2018012230A (es) | Métodos para tratar enfermedades oculares. | |
| BR112017008097A2 (pt) | método para tratar condições oculares | |
| EA201791538A1 (ru) | Способ предотвращения или лечения потери слуха | |
| MX2018005987A (es) | Compuestos heterociclicos para el tratamiento de enfermedades. | |
| HUE052098T2 (hu) | Prohemosztatikus fehérjék vérzés kezelésére | |
| IL252707A0 (en) | Compositions and methods for treating diseases and conditions | |
| CY1125266T1 (el) | To rad1901 για χρηση στη θεραπεια του καρκινου των ωοθηκων | |
| BR112017026193A2 (pt) | agentes de clarificação para bioprocessamento de adsorventes e métodos de produção e uso dos mesmos | |
| IL249483B (en) | Preparation methods for a novel generation of biological safe klh products used for cancer treatment, for the development of conjugated therapeutic vaccines and as challenging agents |